ANEW Medical (NASDAQ:WENA) announced the appointment of Jeffrey LeBlanc as its new CFO, succeeding interim CFO, Edward Cong Wang, the former CFO of Redwoods Acquisition, which ANEW merged with.
ANEW’s portfolio includes its proprietary gene therapy program using DNA and RNA as therapeutics and diagnostics, along with clinical-stage antibody biologics targeting cancer and autoimmune diseases. Additionally, it features Nanoject, a needle-free dry powder jet autoinjector for drug delivery.
Founder and CEO of ANEW, Joseph Sinkule, said, “Jeff LeBlanc is a highly experienced senior executive, and we are absolutely delighted to welcome him to our team.” Dr. Sinkule added, “Jeff has over 20 years of experience in managing financial operations, launching new ventures and achieving successful exits. Earlier in his career, Jeff served in investment roles at Greenlight Capital and GE Capital, after having started his career at McKinsey and Co following his graduation from MIT with a BS in Chemical Engineering and subsequently an MBA from Harvard Business.”
